Breaking News Instant updates and real-time market news.

BIIB

Biogen

$311.59

-1.44 (-0.46%)

, IONS

Ionis Pharmaceuticals

$36.03

-0.61 (-1.66%)

09:08
10/04/16
10/04
09:08
10/04/16
09:08

Biogen could rise $20 or more per share on SMA success, says RBC Capital

RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.

BIIB

Biogen

$311.59

-1.44 (-0.46%)

IONS

Ionis Pharmaceuticals

$36.03

-0.61 (-1.66%)

  • 26

    Oct

  • 06

    Nov

BIIB Biogen
$311.59

-1.44 (-0.46%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/03/16
BMOC
10/03/16
NO CHANGE
Target $304
BMOC
Biogen potential trading opportunity into year-end, says BMO Capital
BMO Capital hosted a call with an expert on Alzheimers that may present a trading opportunity in Biogen (BIIB) shares as we approach sola Phase 3 and aducanumab titration data expected at year end. The expert said evidence supports the amyloid hypothesis of AD outweighs the evidence that undercuts it, but suggested that patient selection and trial design/execution key to demonstrating benefit to support regulatory approval. He estimated that Lilly's (LLY) EXPEDITION-3 trial has a ~60% probability of success, with Biogen's aducanumab greater than70% as long as rates of ARIA-E can be reduced with titration. Analyst Ian Somaiya believes positive Phase III Sola data could provide a positive read through to aducanumab and results in Biogen shares trading up 20-25%. If Sola misses, aducanumab's ability to clear beta amyloid oligomers & plaques and in our opinion a better trial design could limit downside in shares to approximately 10%. Somaiya rates Biogen a Market Perform with a $304 price target.
IONS Ionis Pharmaceuticals
$36.03

-0.61 (-1.66%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.

TODAY'S FREE FLY STORIES

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

, DDAIF

Daimler AG

$90.25

1.44 (1.62%)

06:41
01/16/18
01/16
06:41
01/16/18
06:41
Periodicals
Fiat Chrysler, Daimler warn over Europe's emissions targets, FT says »

Fiat Chrysler (FCAU) and…

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

DDAIF

Daimler AG

$90.25

1.44 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAC

GAP Airports

$102.12

0.45 (0.44%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Earnings
GAP Airports sees FY18 total revenue growth 13%, plus or minus 1% »

FY18 revenue consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.76

-0.26 (-1.37%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Hot Stocks
GE Capital to fund contributions, suspend dividend to GE for forseeable future »

GE Capital to fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

GE

General Electric

$18.76

-0.26 (-1.37%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Hot Stocks
GE to take $6.2B charge in Q4 on insurance operations »

GE announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

K

Kellogg

$64.69

-1.29 (-1.96%)

, CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Recommendations
Kellogg, Campbell Soup analyst commentary  »

Kellogg added to U.S.…

K

Kellogg

$64.69

-1.29 (-1.96%)

CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

06:37
01/16/18
01/16
06:37
01/16/18
06:37
Upgrade
Campbell Soup rating change  »

Campbell Soup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$24.01

0.63 (2.69%)

06:36
01/16/18
01/16
06:36
01/16/18
06:36
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$126.96

1.52 (1.21%)

06:35
01/16/18
01/16
06:35
01/16/18
06:35
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$27.53

0.38 (1.40%)

06:34
01/16/18
01/16
06:34
01/16/18
06:34
Periodicals
Airbus prepared to shut down production of A380 superjumbo, FT reports »

Airbus is ready to shut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$34.63

2.54 (7.92%)

06:34
01/16/18
01/16
06:34
01/16/18
06:34
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.81

1.47 (8.48%)

06:33
01/16/18
01/16
06:33
01/16/18
06:33
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$36.73

0.53 (1.46%)

06:32
01/16/18
01/16
06:32
01/16/18
06:32
Upgrade
21st Century Fox rating change  »

21st Century Fox upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

DUST

Direxion Daily Gold Miners Bear 3X ETF

$21.30

-1.89 (-8.15%)

06:32
01/16/18
01/16
06:32
01/16/18
06:32
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SP

SP Plus Corp.

$38.00

0.2 (0.53%)

06:31
01/16/18
01/16
06:31
01/16/18
06:31
Hot Stocks
SP Plus Corp. sells joint venture interest in Parkmobile, sees Q1 gain »

SP Plus Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$47.10

-4.42 (-8.58%)

06:31
01/16/18
01/16
06:31
01/16/18
06:31
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$25.85

0.01 (0.04%)

06:30
01/16/18
01/16
06:30
01/16/18
06:30
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLB

Dolby

$65.35

1.06 (1.65%)

06:29
01/16/18
01/16
06:29
01/16/18
06:29
Downgrade
Dolby rating change  »

Dolby downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$144.75

-0.25 (-0.17%)

06:29
01/16/18
01/16
06:29
01/16/18
06:29
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$76.84

1.28 (1.69%)

06:28
01/16/18
01/16
06:28
01/16/18
06:28
Periodicals
Citi results likely 'overwhelmed' by $20B charge due to tax overhaul, WSJ says »

Citigroup's results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

JPM

JPMorgan

$112.67

1.83 (1.65%)

06:28
01/16/18
01/16
06:28
01/16/18
06:28
Hot Stocks
JPMorgan reports December net credit losses 2.43% vs. 2.36% last month »

Reports December 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$4.74

0.01 (0.21%)

06:27
01/16/18
01/16
06:27
01/16/18
06:27
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNV

Innovus Pharmaceuticals

06:27
01/16/18
01/16
06:27
01/16/18
06:27
Hot Stocks
Innovus Pharmaceuticals' hemorrhoid drug Xyralid approved in Canada »

Innovus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$138.19

-0.02 (-0.01%)

06:26
01/16/18
01/16
06:26
01/16/18
06:26
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

$187.95

0.06 (0.03%)

06:25
01/16/18
01/16
06:25
01/16/18
06:25
Recommendations
Tyler Technologies analyst commentary  »

Tyler Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 26

    Feb

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

06:25
01/16/18
01/16
06:25
01/16/18
06:25
Periodicals
Fiat Chrysler's Marchionne says new CEO to be named this year, AP reports »

Fiat Chrysler CEO Sergio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.